Clinical and Research Considerations for Patients With Hypertensive Acute Heart Failure: A Consensus Statement from the Society for Academic Emergency Medicine and the Heart Failure Society of America Acute Heart Failure Working Group

Academic Emergency Medicine

Volumn 23, Issue 8, 2016, Pages 922-931

  Collins, Sean P ^a   Levy, Phillip D ^b   Martindale, Jennifer L ^c   Dunlap, Mark E ^d   Storrow, Alan B ^a   Pang, Peter S ^e   Albert, Nancy M ^f   Felker, G Michael ^g   Fermann, Gregory J ^h   Fonarow, Gregg C ⁱ   Givertz, Michael M ^j   Hollander, Judd E ^k   Lanfear, David E ^l   Lenihan, Daniel J ^a   Lindenfeld, JoAnn M ^a   Peacock, W Frank ^m   Sawyer, Douglas B ⁿ   Teerlink, John R ^o   Butler, Javed ^p  

^a VANDERBILT UNIVERSITY   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Downstate Health Sciences University   (United States)

^d CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e INDIANA UNIVERSITY   (United States)

^f LERNER RESEARCH INSTITUTE   (United States)

^g DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j HARVARD MEDICAL SCHOOL   (United States)

^k THOMAS JEFFERSON UNIVERSITY   (United States)

^l HENRY FORD HEALTH SYSTEM   (United States)

^m BAYLOR COLLEGE OF MEDICINE   (United States)

ⁿ MAINE MEDICAL CENTER   (United States)

^o VETERANS AFFAIRS MEDICAL CENTER   (United States)

^p STONY BROOK UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GLYCERYL TRINITRATE; LOOP DIURETIC AGENT; NITROPRUSSIDE SODIUM;

ACUTE HEART FAILURE; AGE; ARTICLE; BLOOD PRESSURE; EMERGENCY MEDICINE; EMERGENCY WARD; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HUMAN; HYPERTENSION; KIDNEY FUNCTION; MEDICAL SOCIETY; PATHOPHYSIOLOGY; PHENOTYPE; PRIORITY JOURNAL; TREATMENT RESPONSE; VASCULAR DISEASE; VASODILATATION;

EID: 84982889615     PISSN: 10696563     EISSN: 15532712     Source Type: Journal    
DOI: 10.1111/acem.13025     Document Type: Article

References (91)

1. Viau DM, Sala-Mercado JA, Spranger MD, O'Leary DS, Levy PD. The pathophysiology of hypertensive acute heart failure. Heart 2015;101:1861–7.
2. Gheorghiade M, Filippatos G, De Luca L, Burnett J. Congestion in acute heart failure syndromes: an essential target of evaluation and treatment. Am J Med 2006;119:S3–10.
3. Metra M, Teerlink JR, Voors AA, et al. Vasodilators in the treatment of acute heart failure: what we know, what we don't. Heart Fail Rev 2009;14:299–307.
4. Galderisi M. Diagnosis and management of left ventricular diastolic dysfunction in the hypertensive patient. Am J Hypertens 2011;24:507–17.
5. Levy P, Ye H, Compton S, et al. Subclinical hypertensive heart disease in black patients with elevated blood pressure in an inner-city emergency department. Ann Emerg Med 2012;60:467–74.e1.
6. Wan SH, Vogel MW, Chen HH. Pre-clinical diastolic dysfunction. J Am Coll Cardiol 2014;63:407–16.
7. Borlaug BA, Lam CS, Roger VL, Rodeheffer RJ, Redfield MM. Contractility and ventricular systolic stiffening in hypertensive heart disease insights into the pathogenesis of heart failure with preserved ejection fraction. J Am Coll Cardiol 2009;54:410–8.
8. Schwartzenberg S, Redfield MM, From AM, Sorajja P, Nishimura RA, Borlaug BA. Effects of vasodilation in heart failure with preserved or reduced ejection fraction implications of distinct pathophysiologies on response to therapy. J Am Coll Cardiol 2012;59:442–51.
9. Sunagawa K, Maughan WL, Burkhoff D, Sagawa K. Left ventricular interaction with arterial load studied in isolated canine ventricle. Am J Physiol 1983;245:H773–80.
10. Chirinos JA, Segers P. Noninvasive evaluation of left ventricular afterload: part 1: pressure and flow measurements and basic principles of wave conduction and reflection. Hypertension 2010;56:555–62.
11. Denardo SJ, Nandyala R, Freeman GL, Pierce GL, Nichols WW. Pulse wave analysis of the aortic pressure waveform in severe left ventricular systolic dysfunction. Circ Heart Fail 2010;3:149–56.
12. Chirinos JA, Segers P. Noninvasive evaluation of left ventricular afterload: part 2: arterial pressure-flow and pressure-volume relations in humans. Hypertension 2010;56:563–70.
13. Gheorghiade M, Adams KF, Cleland JG, et al. Phase III clinical trial end points in acute heart failure syndromes: a virtual roundtable with the Acute Heart Failure Syndromes International Working Group. Am Heart J 2009;157:957–70.
14. Adams KF Jr, Fonarow GC, Emerman CL, et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J 2005;149:209–16.
15. Diercks DB, Peacock WF, Kirk JD, Weber JE. ED patients with heart failure: identification of an observational unit-appropriate cohort. Am J Emerg Med 2006;24:319–24.
16. Fonarow GC, Adams KF Jr, Abraham WT, Yancy CW, Boscardin WJ. Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis. JAMA 2005;293:572–80.
17. Berthelot E, Bihry N, Brault-Melin O, et al. Changes in ventricular-arterial coupling during decongestive therapy in acute heart failure. Eur J Clin Invest 2014;44:982–8.
18. Pieragnoli P, Perego GB, Ricciardi G, et al. Cardiac resynchronization therapy acutely improves ventricular-arterial coupling by reducing the arterial load: assessment by pressure-volume loops. Pacing Clin Electrophysiol 2015;38:431–7.
19. Aroor AR, Demarco VG, Jia G, et al. The role of tissue renin-angiotensin-aldosterone system in the development of endothelial dysfunction and arterial stiffness. Front Endocrinol (Lausanne) 2013;4:161.
20. Shantsila A, Shantsila E, Butt M, Khair OA, Dwivedi G, Lip GY. Ventricular-arterial coupling in obstructive sleep apnea. J Am Soc Hypertens 2014;8:624–9.
21. Bristow JD, Honour AJ, Pickering GW, Sleight P, Smyth HS. Diminished baroreflex sensitivity in high blood pressure. Circulation 1969;39:48–54.
22. Mancia G, Ludbrook J, Ferrari A, Gregorini L, Zanchetti A. Baroreceptor reflexes in human hypertension. Circ Res 1978;43:170–7.
23. Floras JS, Hassan MO, Jones JV, Osikowska BA, Sever PS, Sleight P. Consequences of impaired arterial baroreflexes in essential hypertension: effects on pressor responses, plasma noradrenaline and blood pressure variability. J Hypertens 1988;6:525–35.
24. Sarkar S, Hettrick DA, Koehler J, et al. Improved algorithm to detect fluid accumulation via intrathoracic impedance monitoring in heart failure patients with implantable devices. J Card Fail 2011;17:569–76.
25. Abraham WT, Adamson PB, Bourge RC, et al. Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial. Lancet 2011;377:658–66.
26. Fallick C, Sobotka PA, Dunlap ME. Sympathetically mediated changes in capacitance: redistribution of the venous reservoir as a cause of decompensation. Circ Heart Fail 2011;4:669–75.
27. Stevenson LW, Zile M, Bennett TD, et al. Chronic ambulatory intracardiac pressures and future heart failure events. Circ Heart Fail 2010;3:580–7.
28. MacIver DH, Clark AL. The vital role of the right ventricle in the pathogenesis of acute pulmonary edema. Am J Cardiol 2015;115:992–1000.
29. Wang CS, FitzGerald JM, Schulzer M, Mak E, Ayas NT. Does this dyspneic patient in the emergency department have congestive heart failure? JAMA 2005;294:1944–56.
30. Di Somma S, Lalle I, Magrini L, et al. Additive diagnostic and prognostic value of bioelectrical impedance vector analysis (BIVA) to brain natriuretic peptide ‘grey-zone’ in patients with acute heart failure in the emergency department. Eur Heart J Acute Cardiovasc Care 2014;3:167–75.
31. Blair JE, Brennan JM, Goonewardena SN, Shah D, Vasaiwala S, Spencer KT. Usefulness of hand-carried ultrasound to predict elevated left ventricular filling pressure. Am J Cardiol 2009;103:246–7.
32. Brennan JM, Blair JE, Goonewardena S, et al. A comparison by medicine residents of physical examination versus hand-carried ultrasound for estimation of right atrial pressure. Am J Cardiol 2007;99:1614–6.
33. Miller WL, Mullan BP. Understanding the heterogeneity in volume overload and fluid distribution in decompensated heart failure is key to optimal volume management: role for blood volume quantitation. JACC Heart Fail 2014;2:298–305.
34. Zelis R, Delea CS, Coleman HN, Mason DT. Arterial sodium content in experimental congestive heart failure. Circulation 1970;41:213–6.
35. Zelis R, Mason DT. Diminished forearm arteriolar dilator capacity produced by mineralocorticoid-induced salt retention in man. Implications concerning congestive heart failure and vascular stiffness. Circulation 1970;41:589–92.
36. Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail 2008;10:933–89.
37. Colvin M, Sweitzer NK, Albert NM, et al. Heart Failure in Non-Caucasians, Women, and Older Adults: A White Paper on Special Populations From the Heart Failure Society of America Guideline Committee. J Card Fail 2015;21:674–93.
38. Komajda M, Hanon O, Hochadel M, et al. Contemporary management of octogenarians hospitalized for heart failure in Europe: Euro Heart Failure Survey II. Eur Heart J 2009;30:478–86.
39. Freund Y, Delerme S, Boddaert J, Baker E, Riou B, Ray P. Isosorbide dinitrate bolus for heart failure in elderly emergency patients: a retrospective study. Eur J Emerg Med 2011;18:272–5.
40. Damman K, Valente MA, Voors AA, O'Connor CM, van Veldhuisen DJ, Hillege HL. Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis. Eur Heart J 2014;35:455–69.
41. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013;62:e147–239.
42. Wattad M, Darawsha W, Solomonica A, et al. Interaction between worsening renal function and persistent congestion in acute decompensated heart failure. Am J Cardiol 2015;115:932–7.
43. Goldberg RJ, Ismailov RM, Patlolla V, Lessard D, Spencer FA. Therapies for acute heart failure in patients with reduced kidney function: a community-based perspective. Am J Kidney Dis 2008;51:594–602.
44. Shirakabe A, Hata N, Kobayashi N, et al. Prognostic impact of acute kidney injury in patients with acute decompensated heart failure. Circ J 2013;77:687–96.
45. Butler J, Forman DE, Abraham WT, et al. Relationship between heart failure treatment and development of worsening renal function among hospitalized patients. Am Heart J 2004;147:331–8.
46. Collins S, Storrow AB, Albert NM, et al. Early management of patients with acute heart failure: state of the art and future directions. A consensus document from the Society for Academic Emergency Medicine/Heart Failure Society of America Acute Heart Failure Working Group. J Card Fail 2015;21:27–43.
47. Collins S, Storrow AB, Kirk JD, Pang PS, Diercks DB, Gheorghiade M. Beyond pulmonary edema: diagnostic, risk stratification, and treatment challenges of acute heart failure management in the emergency department. Ann Emerg Med 2008;51:45–57.
48. Gheorghiade M, Braunwald E. A proposed model for initial assessment and management of acute heart failure syndromes. JAMA 2011;305:1702–3.
49. Gheorghiade M, Abraham WT, Albert NM, et al. Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure. JAMA 2006;296:2217–26.
50. Cotter G, Felker GM, Adams KF, Milo-Cotter O, O'Connor CM. The pathophysiology of acute heart failure–is it all about fluid accumulation? Am Heart J 2008;155:9–18.
51. Cotter G, Metra M, Milo-Cotter O, Dittrich HC, Gheorghiade M. Fluid overload in acute heart failure–re-distribution and other mechanisms beyond fluid accumulation. Eur J Heart Fail 2008;10:165–9.
52. Cotter G, Metzkor E, Kaluski E, et al. Randomised trial of high-dose isosorbide dinitrate plus low-dose furosemide versus high-dose furosemide plus low-dose isosorbide dinitrate in severe pulmonary oedema. Lancet 1998;351:389–93.
53. Levy P, Compton S, Welch R, et al. Treatment of severe decompensated heart failure with high-dose intravenous nitroglycerin: a feasibility and outcome analysis. Ann Emerg Med 2007;50:144–52.
54. Peacock WF, Chandra A, Char D, et al. Clevidipine in acute heart failure: results of the A Study of Blood Pressure Control in Acute Heart Failure-A Pilot Study (PRONTO). Am Heart J 2014;167:529–36.
55. Collins SP, Mielniczuk LM, Whittingham HA, Boseley ME, Schramm DR, Storrow AB. The use of noninvasive ventilation in emergency department patients with acute cardiogenic pulmonary edema: a systematic review. Ann Emerg Med 2006;48:260–9, 369.e1–4.
56. Vital FM, Ladeira MT, Atallah AN. Non-invasive positive pressure ventilation (CPAP or bilevel NPPV) for cardiogenic pulmonary oedema. Cochrane Database Syst Rev 2013;5:CD005351.
57. Masip J, Roque M, Sanchez B, Fernandez R, Subirana M, Exposito JA. Noninvasive ventilation in acute cardiogenic pulmonary edema: systematic review and meta-analysis. JAMA 2005;294:3124–30.
58. Gray A, Goodacre S, Newby DE, Masson M, Sampson F, Nicholl J. Noninvasive ventilation in acute cardiogenic pulmonary edema. N Engl J Med 2008;359:142–51.
59. Sharon A, Shpirer I, Kaluski E, et al. High-dose intravenous isosorbide-dinitrate is safer and better than Bi-PAP ventilation combined with conventional treatment for severe pulmonary edema. J Am Coll Cardiol 2000;36:832–7.
60. Collins SP, Pang PS, Lindsell CJ, et al. International variations in the clinical, diagnostic, and treatment characteristics of emergency department patients with acute heart failure syndromes. Eur J Heart Fail 2010;12:1253–60.
61. Sinoway L, Minotti J, Musch T, et al. Enhanced metabolic vasodilation secondary to diuretic therapy in decompensated congestive heart failure secondary to coronary artery disease. Am J Cardiol 1987;60:107–11.
62. Peacock W, Fonarow GC, Emerman CL, Mills RM, Wynne J. Impact of Early Initiation of Intravenous Therapy for Acute Decompensated Heart Failure on Outcomes in ADHERE. Cardiology 2006;107:44–51.
63. Felker GM, Lee KL, Bull DA, et al. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med 2011;364:797–805.
64. Weintraub NL, Collins SP, Pang PS, et al. Acute heart failure syndromes: emergency department presentation, treatment, and disposition: current approaches and future aims: a scientific statement from the American Heart Association. Circulation 2010;122:1975–96.
65. Teerlink JR, Cotter G, Davison BA, et al. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. Lancet 2013;381:29–39.
66. Jordan RA, Seth L, Casebolt P, Hayes MJ, Wilen MM, Franciosa J. Rapidly developing tolerance to transdermal nitroglycerin in congestive heart failure. Ann Intern Med 1986;104:295–8.
67. Sharpe N, Coxon R, Webster M, Luke R. Hemodynamic effects of intermittent transdermal nitroglycerin in chronic congestive heart failure. Am J Cardiol 1987;59:895–9.
68. Alexander P, Alkhawam L, Curry J, et al. Lack of evidence for intravenous vasodilators in ED patients with acute heart failure: a systematic review. Am J Emerg Med 2015;33:133–41.
69. Wakai A, McCabe A, Kidney R, et al. Nitrates for acute heart failure syndromes. Cochrane Database Syst Rev 2013;8:CD005151.
70. Eryonucu B, Guler N, Guntekin U, Tuncer M. Comparison of the effects of nitroglycerin and nitroprusside on transmitral Doppler flow parameters in patients with hypertensive urgency. Ann Pharmacother 2005;39:997–1001.
71. Erickson AL, DeGrado JR, Fanikos JR. Clevidipine: a short-acting intravenous dihydropyridine calcium channel blocker for the management of hypertension. Pharmacotherapy 2010;30:515–28.
72. Swedberg K, Kjekshus J. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). Am J Cardiol 1988;62:60A–6A.
73. Demarco T, Daly PA, Liu M, Kayser S, Parmley WW, Chatterjee K. Enalaprilat, a New Parenteral Angiotensin-Converting Enzyme-Inhibitor - Rapid Changes in Systemic and Coronary Hemodynamics and Humoral Profile in Chronic Heart-Failure. J Am Coll Cardiol 1987;9:1131–8.
74. Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991;325:303–10.
75. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med 1991;325:293–302.
76. Swedberg K, Held P, Kjekshus J, Rasmussen K, Ryden L, Wedel H. Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). N Engl J Med 1992;327:678–84.
77. Annane D, Bellissant E, Pussard E, et al. Placebo-controlled, randomized, double-blind study of intravenous enalaprilat efficacy and safety in acute cardiogenic pulmonary edema. Circulation 1996;94:1316–24.
78. Hamilton RJ, Carter WA, Gallagher EJ. Rapid improvement of acute pulmonary edema with sublingual captopril. Acad Emerg Med 1996;3:205–12.
79. Podbregar M, Voga G, Horvat M, et al. Bolus versus continuous low dose of enalaprilat in congestive heart failure with acute refractory decompensation. Cardiology 1999;91:41–9.
80. Hirschl MM, Binder M, Bur A, et al. Clinical evaluation of different doses of intravenous enalaprilat in patients with hypertensive crises. Arch Intern Med 1995;155:2217–23.
81. Tohmo H, Karanko M, Korpilahti K. Haemodynamic effects of enalaprilat and preload in acute severe heart failure complicating myocardial infarction. Eur Heart J 1994;15:523–7.
82. Collins SP, Storrow AB. Acute heart failure. in: Tintinalli JE, Stapczynski J, Ma O, Cline DM, Yealy D, Meckler GD, eds. Tintinalli's Emergency Medicine: A Comprehensive Study Guide, 8th ed. New York, NY: McGraw-Hill, 2015.
83. Felker GM, Butler J, Collins SP, et al. Heart failure therapeutics on the basis of a biased ligand of the angiotensin-2 type 1 receptor. Rationale and design of the BLAST-AHF study (Biased Ligand of the Angiotensin Receptor Study in Acute Heart Failure). JACC. Heart Fail 2015;3:193–201.
84. Metra M, Cotter G, Davison BA, et al. Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) development program: correlation with outcomes. J Am Coll Cardiol 2013;61:196–206.
85. Styron JF, Jois-Bilowich P, Starling R, et al. Initial emergency department systolic blood pressure predicts left ventricular systolic function in acute decompensated heart failure. Congest Heart Fail 2009;15:9–13.
86. Teerlink JR, McMurray JJ, Bourge RC, et al. Tezosentan in patients with acute heart failure: design of the Value of Endothelin Receptor Inhibition with Tezosentan in Acute heart failure Study (VERITAS). Am Heart J 2005;150:46–53.
87. McMurray JJ, Teerlink JR, Cotter G, et al. Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials. JAMA 2007;298:2009–19.
88. VMAC Investigators. Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA 2002;287:1531–40.
89. Teerlink JR, Metra M, Felker GM, et al. Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study. Lancet 2009;373:1429–39.
90. O'Connor CM, Starling RC, Hernandez AF, et al. Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med 2011;365:32–43.
91. Gheorghiade M, Greene SJ, Filippatos G, et al. Cinaciguat, a soluble guanylate cyclase activator: results from the randomized, controlled, phase IIb COMPOSE programme in acute heart failure syndromes. Eur J Heart Fail 2012;14:1056–66.